Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.
Administration, Oral
Alendronate
/ pharmacology
Animals
Anticarcinogenic Agents
/ pharmacology
Apoptosis
/ drug effects
Azoxymethane
/ toxicity
Cell Proliferation
/ drug effects
Colonic Neoplasms
/ chemically induced
Dose-Response Relationship, Drug
Drug Synergism
Drug Therapy, Combination
Humans
Male
Metformin
/ pharmacology
Neoplasms, Experimental
/ chemistry
Rats
Rats, Inbred F344
Zoledronic Acid
/ pharmacology
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
08
2019
revised:
11
10
2019
accepted:
04
11
2019
pubmed:
9
11
2019
medline:
30
3
2021
entrez:
9
11
2019
Statut:
ppublish
Résumé
Recent observational studies suggest that bisphosphonates (BP) and antidiabetic drugs are associated with colorectal cancer risk reduction. Hence, we evaluated the colorectal cancer preventive effects of BPs (zometa and fosamax), individually and when combined with metformin, in azoxymethane-induced rat colon cancer model. Rat (30/group) were randomized and treated subcutaneously with azoxymethane to induce colorectal cancer. Dietary intervention with zometa or fosamax (0, 20, or 100 ppm) or metformin (1,000 ppm) or the combinations (zometa/fosamax 20 ppm plus metformin 1,000 ppm) began 4 weeks after azoxymethane treatment, at premalignant lesions stage. Rats were killed 40 weeks post drug intervention to assess colorectal cancer preventive efficacy. Dietary zometa (20 ppm) inhibited noninvasive adenocarcinomas multiplicity by 37% (
Identifiants
pubmed: 31699708
pii: 1940-6207.CAPR-19-0265
doi: 10.1158/1940-6207.CAPR-19-0265
pmc: PMC7007371
mid: NIHMS1542654
doi:
Substances chimiques
Anticarcinogenic Agents
0
Zoledronic Acid
6XC1PAD3KF
Metformin
9100L32L2N
Azoxymethane
MO0N1J0SEN
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-194Subventions
Organisme : NCI NIH HHS
ID : N01CN53300
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213987
Pays : United States
Organisme : BLRD VA
ID : I01 BX003198
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA109247
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA225520
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN053300
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201200013I
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Drug Deliv. 2015 Jan;22(1):1-9
pubmed: 24404750
Cancer Invest. 2011 Oct;29(8):533-41
pubmed: 21843051
Mol Cancer Ther. 2014 Nov;13(11):2583-94
pubmed: 25193509
Mol Pharm. 2015 Nov 2;12(11):3783-91
pubmed: 26430787
Bonekey Rep. 2013 Feb 06;2:267
pubmed: 24422040
PLoS One. 2014 May 06;9(5):e96801
pubmed: 24802416
BMJ. 2005 Jun 4;330(7503):1304-5
pubmed: 15849206
Am J Cancer Res. 2016 May 01;6(5):894-909
pubmed: 27293987
J Bone Miner Res. 2000 Aug;15(8):1467-76
pubmed: 10934645
Clin Gastroenterol Hepatol. 2013 Mar;11(3):232-9.e1
pubmed: 23220165
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000
pubmed: 25453078
Bone. 2005 Jul;37(1):74-86
pubmed: 15894525
Int J Cancer. 2016 Mar 15;138(6):1516-27
pubmed: 26437179
Trends Mol Med. 2004 Jul;10(7):337-43
pubmed: 15242682
J Clin Oncol. 2015 Apr 1;33(10):1186-90
pubmed: 25713431
J Clin Oncol. 2011 Mar 20;29(9):1146-50
pubmed: 21321296
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2013 Feb 10;31(5):623-30
pubmed: 23269990
Br J Cancer. 2001 Apr 6;84(7):951-8
pubmed: 11286476
PLoS One. 2013 Aug 02;8(8):e71583
pubmed: 23936520
Inflamm Bowel Dis. 2016 Nov;22(11):2549-2561
pubmed: 27760076
Annu Rev Pharmacol Toxicol. 1997;37:143-66
pubmed: 9131250
Br J Pharmacol. 2007 May;151(2):206-15
pubmed: 17375077
Cancer Prev Res (Phila). 2019 Nov;12(11):751-762
pubmed: 31530543
N Engl J Med. 1996 Feb 29;334(9):574-9
pubmed: 8569826
Br J Cancer. 2010 Mar 2;102(5):799-802
pubmed: 20160722
Cancer Med. 2013 Feb;2(1):99-107
pubmed: 24133632
Clin Cancer Res. 2017 Apr 1;23(7):1684-1689
pubmed: 27683176
PLoS One. 2013 Nov 21;8(11):e81264
pubmed: 24278407
Cancer Res. 2009 Oct 1;69(19):7507-11
pubmed: 19752085
Clin Calcium. 2016;26(11):1561-1570
pubmed: 27777389
Osteoporos Int. 2012 Nov;23(11):2693-701
pubmed: 22392160
Mol Pharmacol. 2007 Jan;71(1):333-43
pubmed: 17050806
Cancer Lett. 2009 Jun 8;278(1):17-26
pubmed: 19233551
Int J Oncol. 2015 Jul;47(1):211-9
pubmed: 25955490